NASDAQ:CRSP (CRISPR Therapeutics)
About CRSP
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
CRISPR Therapeutics (NASDAQ: CRSP) Latest News

Investing Articles
This growth stock jumped 77%! I think it can go much higher

Investing Articles
If I’d invested £1k in CRISPR Therapeutics shares on January 3, here’s what I’d have now!

Investing Articles
Growth stocks in focus: can buying CRISPR Therapeutics at $50 make me rich?

Investing Articles
Here’s what Cathie Wood has been buying for her flagship Ark fund!

Investing Articles
My top growth stocks to buy after the Nasdaq correction!
